Chiromics LLC and Bristol-Myers Squibb have entered into strategic research alliance to discover and optimize novel classes of small molecules against multiple therapeutic targets. The collaboration includes non-exclusive license to Chiromics’ chemical compound library and an exclusive license to a chemical compound collection.
Chiromics’ chemical compound collection and Chalis, the company’s hit recognition algorithm for affinity selection, will be used for the identification of new lead molecules that are complementary to conventional high throughput screening processes.
In a joint statement, Chiromics’ founders, David MacMillan, Ph.D. and James S. McDonnell, said, “We are delighted that BMS has chosen Chiromics as a drug discovery partner based on their proven commitment to innovation and reputation as a strong collaborator with biotech companies. This collaboration further authenticates that Chiromics’ chemical technology and discovery platform is a unique gateway to a new set of small molecules for drug discovery.”